-- Kymera Therapeutics (KYMR) shares were down 3% in Thursday trading after it reported a Q1 loss of $0.71 per share, narrowing from a loss of $0.82 a year earlier.
Analysts surveyed by FactSet expected a loss of $0.88.
Collaboration revenue for the quarter ended March 31 was $34.4 million, up from $22.1 million a year earlier.
Analysts polled by FactSet expected $8.3 million.
As of March 31, Kymera Therapeutics said it had $1.55 billion in cash, cash equivalents, and investments, which it expects to provide the company with a cash runway into 2029.
Price: $79.23, Change: $-2.28, Percent Change: -2.80%